摘要
目的 观察褪黑素治疗慢性精神分裂症患者迟发性运动障碍（TD）的临床疗效和不良反应.方法 选择76例有迟发性运动障碍的精神分裂症住院患者,按照入组顺序用随机数字表将患者分为褪黑素治疗组（以下简称褪黑素组,39例）和对照组（37例）.褪黑素组患者每晚服用褪黑素1次（9 mg/次）,对照组患者只维持常规治疗 观察期均为12周.76例患者治疗前和治疗第4,8,12周末盲法采用异常不自主运动量表（AIMS）评定TD疗效,采用治疗中需处理的不良反应症状量表（TESS）评定不良反应.结果 治疗第4,8,12周末,对照组患者AIMS总分较治疗前的差异均无统计学意义（配对t检验,P均〉0.05） 褪黑素组患者AIMS总分均较治疗前显著降低,差异有统计学意义（配对t检验,P均〈0.05）,治疗第12周末舌部、上肢的TD症状较治疗前显著降低,差异均有统计学意义（配对t检验,P均〈0.05）.治疗第8,12周末两组AIMS总分差异有统计学意义（t检验,P〈0.05）.褪黑素组和对照组治疗各时点TESS总分与治疗前比较,褪黑素组患者治疗第4,8,12周末较治疗前均显著降低,差异均有统计学意义（配对t检验,P均〈0.05） 而对照组及两组间的差异均无统计学意义（t检验,P均〉0.05）.结论 褪黑素治疗慢性精神分裂症患者TD有效,对舌和上肢的症状效果明显,无不良反应.
Objective To explore the effectiveness and side effects of melatonin in treatment of tardive dyskinesia in chronic schizophrenic inpatients.Methods Seventy-six inpatients who met with the criteria for schizophrenia （CCMD-3） and tardive dyskinesia （TD） [the Abnormal Involuntary Movement Scale （AIMS） score〉3] were randomly divided into the melatonin group （n=39） and control group （n = 37）.The patients in melatonin group were given melatonin 9 mg once in the evening, and the controls only received route treatment.The efficacy and safety were assessed with the AIMS and Treatment Emergent Symptoms Scale （TESS） before treatment and at the end of 4,8,12 weeks.Results The total AIMS score in melatonin group decreased significantly after 4, 8, 12 week treatment compared with pretreatment （Paired t-test,P 〈0.05 ）.The tongue and upper limbs of TD symptoms decreased significantly after 12 week treatment in the melatonin group （ P〈0.05 ）.The total AIMS score after 8, 12 week treatment was significantly lower in melatonin group than control group （ P〈0.05）.There were no significant differences in TESS total score between both groups after 4,8,12 week treatment（P,〈 0.05）.Conclusions It indicates that melatonin is effective and safe in the treatment of the chronic schizophrenic inpatients with TD,especially for the tongue and upper limb symptoms.
出处
《中华精神科杂志》
CAS
CSCD
北大核心
2010年第1期28-30,共3页
Chinese Journal of Psychiatry
